Table 1. Baseline characteristics.
| Variable | Best treatment outcome | Total N=70 | P-value2 | ||
|---|---|---|---|---|---|
| PR N=4 | SD N=38 | PD N=22 | |||
| Age | 0.01 | ||||
| N | 4 | 38 | 22 | 70 | |
| Median [Q1, Q3] | 67.5 [63.8, 71.8] | 58 [53.2, 65] | 54.5 [52.2, 58.8] | 56.5 [53, 63] | |
| Sex | 0.22 | ||||
| Female | 1 (25) | 11 (28.95) | 11 (50) | 24 (34.29) | |
| Male | 3 (75) | 27 (71.05) | 11 (50) | 46 (65.71) | |
| Town of Residence | 1 | ||||
| Local | 2 (50) | 22 (57.89) | 12 (54.55) | 40 (57.14) | |
| Out of Town | 2 (50) | 16 (42.11) | 10 (45.45) | 30 (42.86) | |
| Ethnicity | 0.11 | ||||
| White | 4 (100) | 26 (68.42) | 10 (45.45) | 41 (58.57) | |
| Hispanic | 0 (0) | 12 (31.58) | 11 (50) | 28 (40) | |
| Other | 0 (0) | 0 (0) | 1 (4.55) | 1 (1.43) | |
| ECOG performance status | 0.02 | ||||
| 0 | 1 (25) | 13 (34.21) | 1 (4.55) | 16 (23.19) | |
| ≥1 | 3 (75) | 25 (65.79) | 21 (95.45) | 53 (76.81) | |
| No of metastatic sites | 0.11 | ||||
| 1 | 1 (25) | 9 (23.68) | 1 (4.55) | 11 (15.71) | |
| ≥2 | 3 (75) | 29 (76.32) | 21 (95.45) | 59 (84.29) | |
| Nephrectomy | 1 | ||||
| Yes | 4 (100) | 35 (94.59) | 19 (95) | 63 (94.03) | |
| No | 0 (0) | 2 (5.41) | 1 (5) | 4 (5.97) | |
| Tumor histology | 0.13 | ||||
| Clear cell | 4 (100) | 27 (72.97) | 12 (54.55) | 47 (68.12) | |
| Non clear cell/Mixed | 0 (0) | 10 (27.03) | 10 (45.45) | 22 (31.88) | |
| No of prior treatment | 0.26 | ||||
| 1 | 2 (50) | 20 (58.82) | 6 (35.29) | 31 (50.82) | |
| ≥2 | 2 (50) | 14 (41.18) | 11 (64.71) | 30 (49.18) | |
| Type of prior treatment | 0.89 | ||||
| TKI | 1 (25) | 5 (13.16) | 3 (14.29) | 9 (13.04) | |
| IL2 | 1 (25) | 8 (21.05) | 2 (9.52) | 14 (20.29) | |
| Bevacizumab | 0 (0) | 1 (2.63) | 2 (9.52) | 3 (4.35) | |
| Chemotherapy | 0 (0) | 4 (10.53) | 4 (19.05) | 8 (11.59) | |
| Clinical trial | 1 (25) | 4 (10.53) | 1 (4.76) | 6 (8.7) | |
| Multiple | 1 (25) | 11 (28.95) | 6 (28.57) | 21 (30.43) | |
| Other | 0 (0) | 5 (13.16) | 3 (14.29) | 8 (11.59) | |
| Type of phase 1 trial | 0.68 | ||||
| Single biological agent | 3 (75) | 27 (72.97) | 12 (60) | 46 (68.66) | |
| Combination therapy | 1 (25) | 9 (24.32) | 6 (30) | 18 (26.87) | |
| Chemotherapy | 0 (0) | 1 (2.7) | 2 (10) | 3 (4.48) | |
| Reason to come off study | 0.23 | ||||
| progression | 3 (75) | 31 (81.58) | 21 (95.45) | 55 (78.57) | |
| Toxicity | 0 (0) | 2 (5.26) | 1 (4.55) | 7 (10) | |
| Patient preference/Other | 1 (25) | 5 (13.16) | 0 (0) | 8 (11.43) | |
| Dose reduction | 0.01 | ||||
| Yes | 1 (25) | 10 (27.03) | 0 (0) | 11 (16.18) | |
| No | 3 (75) | 27 (72.97) | 21 (100) | 57 (83.82) | |
| Site of metastases | < 0.001 | ||||
| Non liver | 4 (100) | 36 (94.74) | 12 (54.55) | 58 (82.86) | |
| Liver | 0 (0) | 2 (5.26) | 10 (45.45) | 12 (17.14) | |
| Treatment on progression | < 0.001 | ||||
| Another trial | 1 (25) | 12 (31.58) | 5 (22.73) | 18 (25.71) | |
| Off trial treatment | 3 (75) | 19 (50) | 3 (13.64) | 28 (40) | |
| No treatment/supportive care | 0 (0) | 1 (2.63) | 12 (54.55) | 14 (20) | |
1
Six best treatment outcomes on CT were missing.
2
Kruskal-Wallis test was used for continuous outcomes and Fisher's Exact test for categorical outcomes.